The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Transcatheter Aortic Valve Implantation. Where are we?
Peter P. T. de Jaegere1*, MD; Carlos Ruiz2, MD; Philipp Bonhoeffer3, MD; Alec Vahanian4, MD; Jean Marco5, MD; Patrick W. Serruys1, MD
1. Department of Cardiology, Erasmus MC Rotterdam, The Netherlands; 2. Department of Interventional Cardiology, Lenox Hill Heart and Vascular Institute of New York, New York, USA; 3. Department of Paediatric Cardiology, Great Ormond Street Hospital, Londo
Prospering from the know-how of percutaneous coronary angioplasty, coronary stents and the vast surgical experience with bioprosthetic valves, transcatheter aortic valve implantation (TAVI) – also called percutaneous aortic valve replacement or PAVR - has become a daily clinical reality. It was initially performed via the complex and hazardous antegrade transseptal approach in 2002, which has been replaced by the retrograde transfemoral or antegrade transapical technique1-4. In the beginning, the transfemoral approach required surgical access and/closure of the femoral artery, but became the first truly percutaneous technique of aortic valve replacement in 20065. In 2007 the CoreValve company and Edwards Lifesciences obtained CE ...